How to Buy Trxade Health Stock
Trxade Health Inc
TRxADE HEALTH, Inc. operates as a health services IT company in the United States.
Trxade Health stock last closed at $0.33, down 16.67% from the previous day, and has decreased 79.81% in one year. It has underperformed other stocks in the Pharmaceutical Retailers industry by 0.36 percentage points. Trxade Health stock is currently +29.48% from its 52-week low of $0.25, and -81.84% from its 52-week high of $1.79.
As of Jun 2, 2023, there are 10.21M MEDS shares outstanding. The market cap of MEDS is $3.32M. In the last 24 hours, 480,218 MEDS shares were traded.
How to Buy Trxade Health Stock
Not sure how to invest in Trxade Health stock? Here's how.
- Decide where to buy Trxade Health stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Trxade Health stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your investment account: Pick your method of payment and add your details.
- Evaluate Trxade Health stock: The Trxade Health ticker symbol is MEDS. Is Trxade Health stock a good investment? Should you buy shares of MEDS? How do MEDS's underlying business fundamentals look? Do top analysts think Trxade Health is a good buy? Why has MEDS's stock price moved recently? (Hint: Our stock research tools can help you evaluate if MEDS is a good stock to buy).
- Make your MEDS buy order: Decide if you will purchase MEDS shares at the current market price or use a limit order to buy MEDS stock at a particular price.
- Get updates on your MEDS position: Create a watchlist to keep tabs on your position in Trxade Health stock.
Step 1: Decide where to buy Trxade Health stock
You will need a brokerage account in order to access the NASDAQ market and buy MEDS stock.
Our preferred brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world markets: From Tech to Industrials, New York to Shanghai — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you are able to invest in MEDS today.
How to Create a New Account on eToro
- Click here to get started.
- Enter your personal details to open a new brokerage account.
- Send your data by hitting the "Create Account" button.
Step 3: Fund your investment account
Now that you have opened your account on the greatest app to buy stocks, you need to deposit funds:
Check out the tutorial below if you need help depositing money into your investment account.
Step 4: Evaluate Trxade Health stock
After you have decided on the best place to buy Trxade Health stock, it's important to analyze their stock prior to investing, so you can understand the risk as well as the upside.
Trxade Health stock quick numbers
MEDS Due Diligence Checks
WallStreetZen was created to help average investors perform more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on MEDS's stock page.
Is MEDS stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge MEDS's intrinsic value.
Using relative valuations measures:
- MEDS could be overvalued based on its P/B ratio of 5.07x, relative to Pharmaceutical Retailers industry P/B ratio of 1.33x
You can access additional valuation analysis on MEDS's stock here.
Is MEDS a healthy company?
Positive Health Checks:
- Total MEDS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the MEDS balance sheet.
Negative Health Checks:
- There are more short-term liabilities than short-term assets on the MEDS balance sheet.
- MEDS has a relatively high debt to equity ratio of 5.16.
- MEDS has $1.24M in cash and short term investments. This is not enough to cover its annual cash burn of $1.99M.
- MEDS has cash burn of 1994606. It does not have enough cash and short-term investments to cover this.
- MEDS profit margin has gone up by 0.25 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Trxade Health stock, according to Wall Street analysts?
Out of 3 Equities analysts who research MEDS, the consensus analyst rating on Trxade Health is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they investment advice.
Latest MEDS Analyst Upgrades/Downgrades
Fozia Ahmed, a bottom 36% analyst from EF Hutton assumes MEDS with a strong buy rating and announces their MEDS price target of $1.25, on Jun 1, 2023.
Constantine Davides, a bottom 5% analyst from EF Hutton maintains MEDS with a strong buy rating and lowers their MEDS price target from $1.70 to $1.25, on May 16, 2023.
Allen Klee, a bottom 4% analyst from Maxim Group maintains MEDS with a strong buy rating and lowers their MEDS price target from $2.50 to $1.75, on Mar 28, 2023.
You can dive deeper into what analysts are saying on the Trxade Health stock forecast page.
MEDS Technicals
MEDS Performance Metrics
Last year, MEDS revenue was $10.46M. Over the past five year, MEDS's revenue has gone up by 27.66% per year. This was faster than the Pharmaceutical Retailers industry average of 2.49%.
Dig into MEDS's earnings and revenue performance here.
Latest Insiders Trades at MEDS
Over the past year, insiders at MEDS have bought more shares than they have sold.
Donald G. Fell, Director of MEDS, was the latest MEDS insider to buy. They bought $1,620.00 worth of MEDS shares on Aug 25, 2022.
Research more about who owns MEDS stock here.
Does MEDS provide a stable income stream?
No, Trxade Health doesn't provide an income stream by paying out dividends.
What do other traders have to say about MEDS?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your MEDS buy order
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly sufficient. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, use a limit order.
Hit the Open button and your broker will place your order.
If you want additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get updates on your MEDS position
Now that you own some MEDS stock, you'll want to keep up with your new shares.
Add MEDS to a watchlist to get notified of important updates regarding your MEDS stock.
MEDS Feed
How to Buy Stock in Trxade Health
To reiterate, here are the 6 steps for buying Trxade Health stock:
- Decide where to buy Trxade Health stock
- Sign up for your brokerage account
- Fund your investment account
- Evaluate Trxade Health stock
- Make your MEDS buy order
- Get updates on your MEDS position
If you require a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to track your new investment in Trxade Health, get started below.
Trending Content
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.